Our Pricing

How to Swap From Mounjaro to Wegovy: UK Cost Comparison and Clinical Guidance

Many patients consider a swap from Mounjaro to Wegovy when reviewing their weight loss treatment options, often driven by cost considerations or supply availability. Both medications are highly effective GLP-1 receptor agonists, but they contain different active ingredients—tirzepatide in Mounjaro and semaglutide in Wegovy—which means the transition requires careful clinical oversight. At Cured Pharmacy, our UK-registered prescribers guide patients through this switch safely, with transparent pricing from £124.99 for Wegovy and comprehensive support throughout the process.

Understanding the Swap From Mounjaro to Wegovy: Key Clinical Differences

When you swap from Mounjaro to Wegovy, you're transitioning between two distinct mechanisms of action. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, meaning it activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors [1]. Wegovy (semaglutide) works solely as a GLP-1 receptor agonist [2]. Both medications have demonstrated significant weight loss outcomes in clinical trials, with SURPASS-2 showing tirzepatide achieving up to 12.4kg average weight reduction at 15mg weekly, whilst STEP trials demonstrated semaglutide 2.4mg achieving approximately 15% body weight reduction over 68 weeks [1][2].

The practical difference for patients making this swap lies in dosing schedules and side effect profiles. Both are once-weekly subcutaneous injections, but the titration schedules differ slightly. Wegovy typically starts at 0.25mg weekly and escalates over 16-20 weeks to the maintenance dose of 2.4mg, whereas Mounjaro begins at 2.5mg and can increase to 15mg [3]. Our clinical team at Cured Pharmacy assesses your current Mounjaro dose and treatment duration to determine the most appropriate Wegovy starting point, ensuring continuity of glycaemic control and weight management throughout the transition.

Monthly Cost Analysis: Swap From Mounjaro to Wegovy in the UK

The financial consideration is often the primary driver when patients choose to swap from Mounjaro to Wegovy. At Cured Pharmacy, Wegovy pricing starts from £124.99 per month (reduced from £124.99 with our transparent pricing structure), whilst Mounjaro is priced from £124.99 per month [4]. This represents a potential monthly saving of £124.99 which accumulates to over £124.99 annually for patients on long-term weight management programmes.

It's important to note that both medications require ongoing prescription, meaning costs are recurring. The price difference becomes particularly significant for patients who have achieved their target dose and are on maintenance therapy, where the clinical outcomes between semaglutide 2.4mg and tirzepatide may be comparable for many individuals [2][3]. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), emphasises that cost should never be the sole deciding factor—clinical suitability and individual response remain paramount.

Hidden Costs and Transparent Pricing

Unlike some providers, Cured Pharmacy displays all costs upfront before your clinical consultation. When you swap from Mounjaro to Wegovy through our service, the price you see includes the medication, UK prescriber assessment, and discreet home delivery. There are no hidden consultation fees or subscription charges. New patients can also access £20 off their first order using code Weightlossnew, bringing the initial Wegovy cost down to £124.99 for eligible patients.

Clinical Protocol for the Swap From Mounjaro to Wegovy

The transition process requires individualised assessment by a UK-registered prescriber. There is no universal 'washout period' required when you swap from Mounjaro to Wegovy, as both medications work on related receptor pathways [1][2]. However, the starting dose of Wegovy will depend on your current Mounjaro dose and how long you've been on treatment. Patients already on higher Mounjaro doses (10mg or 15mg) may begin Wegovy at 0.5mg or 1mg rather than the standard 0.25mg starter dose, though this decision rests with the prescribing clinician.

Our clinical team reviews your complete treatment history, including weight loss achieved, side effects experienced, and any concurrent medications. This comprehensive assessment ensures the swap from Mounjaro to Wegovy maintains therapeutic continuity whilst minimising the risk of gastrointestinal side effects, which can occur with GLP-1 medications if dose escalation is too rapid [3]. The online consultation takes under 3 minutes to complete and is reviewed by a UK prescriber within hours.

Monitoring During the Transition Period

After initiating the swap from Mounjaro to Wegovy, patients should monitor for any changes in appetite control, blood glucose levels (if diabetic), and gastrointestinal tolerance. Most patients experience seamless transitions, but some may notice subtle differences in satiety signals or injection site reactions. Our clinical team remains available for follow-up queries, and we recommend patients maintain regular contact with their NHS GP for ongoing weight and metabolic monitoring, particularly during the first 4-8 weeks post-switch.

Efficacy Comparison: What to Expect When You Swap From Mounjaro to Wegovy

Head-to-head trials directly comparing tirzepatide and semaglutide have shown that both medications produce clinically significant weight loss, though tirzepatide demonstrated slightly superior outcomes in some studies [1]. However, individual response varies considerably. When you swap from Mounjaro to Wegovy, you may experience comparable weight loss maintenance, particularly if you've already achieved substantial weight reduction on Mounjaro and are transitioning for cost or availability reasons.

Clinical evidence suggests that patients who respond well to one GLP-1 medication typically respond well to others, as the underlying mechanism—delayed gastric emptying, increased satiety, and reduced appetite—remains consistent [2][3]. The key is maintaining adherence to the weekly injection schedule and continuing lifestyle modifications including dietary changes and physical activity. Weight loss plateaus can occur with any medication, and switching between GLP-1 agents purely to overcome a plateau is generally not recommended without prescriber guidance.

Side Effects and Tolerability When You Swap From Mounjaro to Wegovy

The side effect profile of both medications is similar, with gastrointestinal symptoms being most common. Nausea, diarrhoea, constipation, and abdominal discomfort affect a significant proportion of patients on GLP-1 therapies, though these typically diminish over time [3][4]. When you swap from Mounjaro to Wegovy, you may experience a recurrence of mild nausea during the initial weeks, particularly if starting at a higher Wegovy dose. This is why careful dose selection by your prescriber is crucial.

Some patients report that they tolerate one medication better than the other, which can be unpredictable and relates to individual physiology. If you experienced significant side effects on Mounjaro, this doesn't automatically mean you'll have the same experience with Wegovy, though the possibility exists. Our clinical team documents your previous side effect history to optimise your starting dose and titration schedule. Rare but serious side effects such as pancreatitis, gallbladder disease, and thyroid C-cell tumours have been associated with GLP-1 medications and require immediate medical attention if symptoms develop [3].

Managing Side Effects During the Swap

To minimise side effects when you swap from Mounjaro to Wegovy, our prescribers recommend eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and injecting at a consistent time each week. If side effects become intolerable, dose adjustment or temporary interruption may be necessary, always under prescriber supervision. Never discontinue or alter your dose without clinical guidance, as this can affect both weight management outcomes and metabolic control.

How to Initiate Your Swap From Mounjaro to Wegovy at Cured Pharmacy

Beginning your swap from Mounjaro to Wegovy through Cured Pharmacy is straightforward and fully compliant with UK pharmaceutical regulations. Start by completing our online clinical assessment, which asks detailed questions about your current Mounjaro treatment, weight loss progress, medical history, and any side effects experienced. This questionnaire is reviewed by a UK-registered prescriber (not an algorithm) who determines whether Wegovy is clinically appropriate for you and selects the optimal starting dose.

Once approved, your Wegovy prescription is dispensed by our GPhC-registered pharmacy (registration number 9012511) and dispatched in 100% discreet packaging via next-day delivery across the UK. All medications are genuine, UK-licensed products sourced through regulated channels. Your first order qualifies for £20 off using code Weightlossnew, and ongoing prescriptions are managed through simple reorder processes with regular prescriber reviews to ensure continued suitability. Our team is available on (+44) 116 4646009 for any clinical queries throughout your treatment journey.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 15 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4mg solution for injection in pre-filled pen: Summary of Product Characteristics. UK Public Assessment Report. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.